Can I Take Creatine with Oral Micronized Progesterone (Prometrium)?

At a glance
- Drug / Oral micronized progesterone (Prometrium), 100 to 200 mg taken orally at bedtime
- Supplement / Creatine monohydrate, typically 3 to 5 g per day after a loading phase
- Direct drug-supplement interaction / None identified in pharmacokinetic or pharmacodynamic literature
- Primary monitoring concern / Creatine raises serum creatinine by 10 to 30 µmol/L, which can falsely suggest reduced kidney function
- Renal contraindication / Creatine is not recommended if eGFR is below 60 mL/min/1.73 m²
- Progesterone metabolism / Hepatic via CYP2C19 and CYP3A4; creatine does not inhibit or induce these enzymes
- Recommended action / Obtain a baseline BMP or CMP before starting creatine; inform your prescriber
- Timing separation / No clinically required dose-separation window between the two agents
What the Interaction Actually Is (and What It Is Not)
Oral micronized progesterone and creatine do not interact through shared enzymes, receptor sites, or overlapping metabolic pathways. The concern that does exist is indirect: creatine supplementation reliably increases serum creatinine, and serum creatinine is a standard lab marker ordered during HRT monitoring. A prescriber who does not know a patient takes creatine may misread an elevated creatinine as early renal impairment rather than a benign supplement effect.
Pharmacokinetic Profile of Oral Micronized Progesterone
Prometrium is absorbed through the gastrointestinal tract, undergoes first-pass hepatic metabolism, and is primarily processed by CYP2C19 and CYP3A4 [1]. Peak plasma concentrations occur roughly 2 to 3 hours after an oral dose. The drug does not depend on renal clearance for elimination, which means kidney function does not materially alter progesterone exposure in patients with mild-to-moderate renal changes [2].
How Creatine Is Handled by the Body
Creatine monohydrate is absorbed in the small intestine and stored predominantly in skeletal muscle as phosphocreatine. A small, predictable fraction of creatine and phosphocreatine is nonenzymatically converted to creatinine and excreted renally [3]. Because this conversion adds to the endogenous creatinine load, serum creatinine rises by roughly 10 to 30 µmol/L during supplementation even when kidney function is entirely normal [4]. The kidneys themselves are not damaged by this process in people with healthy baseline renal function.
Why These Two Pathways Do Not Overlap
Progesterone metabolism is hepatic and cytochrome-P450-dependent. Creatine metabolism is a non-enzymatic, non-CYP process occurring in muscle and kidney tubules. A 2021 narrative review in the Journal of the International Society of Sports Nutrition confirmed creatine has no clinically meaningful effect on hepatic CYP enzyme activity [5]. No published trial, case report, or regulatory safety communication has documented a direct interaction between progesterone formulations and creatine supplementation.
The Creatinine Elevation Problem in HRT Monitoring
This is the practical issue that warrants attention. Oral micronized progesterone is prescribed most often for endometrial protection in postmenopausal women on estrogen therapy [6]. Standard of care includes periodic metabolic panels. If creatinine rises after creatine supplementation begins, a clinician may order additional nephrology workup or, in a worst case, reduce progesterone dose unnecessarily.
How Much Does Creatine Raise Creatinine?
A randomized crossover study (N=18) published in Medicine and Science in Sports and Exercise found that five days of creatine loading at 20 g/day raised mean serum creatinine by 23 µmol/L above baseline, while a maintenance dose of 5 g/day produced a smaller but sustained rise of approximately 10 µmol/L [4]. These elevations fall within or just above the normal reference range for many labs, which means the result may flag as "high" without representing any actual kidney injury.
The International Society of Sports Nutrition (ISSN) 2017 position stand stated: "Creatine supplementation does not increase the risk for kidney disease in healthy individuals, but caution is warranted in those with pre-existing renal disease" [5]. That same document reviewed over 500 studies and found no evidence of renal pathology from creatine in people with eGFR above 60 mL/min/1.73 m².
Distinguishing Supplement Effect from True Renal Dysfunction
Two strategies separate a creatine-related creatinine bump from genuine renal impairment:
-
Cystatin C measurement. Cystatin C is a renal filtration marker unaffected by muscle mass or dietary creatine intake. A 2012 meta-analysis in American Journal of Kidney Diseases (N=5,352) confirmed cystatin C outperforms serum creatinine for detecting early CKD in patients with high muscle mass or dietary supplements that alter creatinine production [7].
-
Baseline creatinine before starting creatine. If a pre-supplementation value is on file, any subsequent rise can be contextualized. A rise from 72 µmol/L to 85 µmol/L after creatine loading is interpretable. A rise to 85 µmol/L with no baseline is ambiguous.
When to Pause or Avoid Creatine on HRT
Patients already managing CKD stage 3 or worse (eGFR <60 mL/min/1.73 m²) should discuss creatine supplementation with their nephrologist before starting, regardless of concurrent progesterone use [5]. For women on Prometrium who have normal renal function, the creatinine elevation does not require stopping either agent. It requires documentation.
Oral Micronized Progesterone: Clinical Background
Approved Indications and Standard Dosing
The FDA approved Prometrium (progesterone, USP) as micronized capsules in 100 mg and 200 mg strengths [1]. For endometrial protection in non-hysterectomized postmenopausal women receiving conjugated estrogens, the standard regimen is 200 mg nightly for 12 days per 28-day cycle, or 100 mg nightly continuously [1]. The bedtime dosing recommendation exists because oral progesterone produces sedative metabolites (allopregnanolone and pregnanolone) that cause drowsiness in approximately 30% of users [2].
Safety Profile Relevant to Supplement Co-administration
The FDA prescribing information lists thromboembolic events, breast cancer risk (in combination estrogen-progestogen therapy), and cardiovascular effects as the primary serious risks [1]. None of these risks are modified by creatine supplementation. The Women's Health Initiative Memory Study (WHIMS) examined cognitive outcomes in women taking conjugated equine estrogen plus medroxyprogesterone acetate, not micronized progesterone, but it remains the most cited safety reference for combination HRT [8]. Micronized progesterone is considered to carry a more favorable cardiovascular and metabolic profile than synthetic progestins, a conclusion supported by the E3N cohort study (N=80,377) published in Breast Cancer Research and Treatment [9].
Drug Interactions That Do Matter for Prometrium
CYP3A4 inhibitors (ketoconazole, clarithromycin, grapefruit juice in large quantities) can increase progesterone plasma levels [1]. CYP3A4 inducers (rifampin, carbamazepine) may reduce efficacy. Creatine is neither. Patients combining Prometrium with sedatives, benzodiazepines, or opioids should be aware of additive CNS depression given progesterone's neuroactive steroid metabolites [2]. This additive sedation risk is unrelated to creatine.
Creatine Supplementation: Evidence Summary
Efficacy in Women and Perimenopausal Populations
Creatine monohydrate is one of the most studied ergogenic supplements in sports medicine. A 2021 systematic review in Nutrients (22 randomized controlled trials, N=721 female participants) found creatine supplementation produced statistically significant improvements in lean mass (mean difference 0.9 kg, 95% CI 0.4 to 1.4 kg, P<0.001) and upper-body strength in women [10]. A smaller but growing body of research suggests creatine may support bone mineral density and cognitive performance in peri- and postmenopausal women, populations that overlap directly with Prometrium users [11].
Standard Dosing Protocols
The ISSN endorses two approaches [5]:
- Loading protocol. 20 g/day divided into four 5 g doses for 5 to 7 days, followed by 3 to 5 g/day maintenance. This saturates muscle creatine stores faster but produces a more pronounced early creatinine spike.
- No-load protocol. 3 to 5 g/day from the outset. Muscle saturation occurs within approximately 28 days. The creatinine elevation is smaller and develops more gradually.
For women on HRT who want the easiest monitoring picture, the no-load protocol at 3 to 5 g/day is the simpler choice.
Timing Relative to Prometrium
No pharmacokinetic data require separation of creatine and progesterone doses. Prometrium is taken at bedtime. Creatine is most commonly taken around exercise, which is typically morning or afternoon for most patients. In practice, the two are separated by several hours simply by routine daily schedules. If a patient prefers to take creatine at night with food (food increases creatine absorption slightly), doing so at the same time as Prometrium does not create an interaction.
Practical Clinical Guidance for Patients Already Taking Both
The following step-by-step framework is designed for patients currently prescribed oral micronized progesterone who want to start creatine, or who have already started and are wondering what to do.
Step 1. Notify your prescriber. Tell your HRT provider before starting creatine. This is not because the combination is dangerous. It is so that your creatinine result on the next metabolic panel is interpreted correctly.
Step 2. Obtain a baseline creatinine or BMP. If you have a recent result (within 3 months, before creatine began), you are already set. If not, ask for one before your first dose of creatine.
Step 3. Choose the no-load protocol if renal status is uncertain. Starting at 3 to 5 g/day avoids the sharper creatinine rise associated with a 20 g/day loading phase.
Step 4. Recheck creatinine at 6 to 8 weeks. This gives your provider a post-supplementation value. If cystatin C is available at your lab, requesting it alongside creatinine is ideal.
Step 5. Continue Prometrium as prescribed. Do not alter your progesterone dose or timing based on creatine supplementation. No dosing adjustment is warranted.
Step 6. Flag symptoms promptly. Swelling, decreased urine output, or flank pain are not expected and should prompt immediate contact with your provider. These would signal an independent renal issue unrelated to either agent.
Populations Requiring Additional Caution
Women with Pre-Existing Kidney Disease
Creatine is not advised without nephrology consultation for patients with eGFR <60 mL/min/1.73 m² [5]. Progesterone dosing does not change in mild renal impairment because the drug is hepatically cleared, but an already-elevated creatinine baseline makes supplement-driven changes harder to interpret [1].
Women with Diabetes on HRT
Type 2 diabetes is associated with diabetic nephropathy, which can present with normal or near-normal creatinine in early stages. The American Diabetes Association 2024 Standards of Care recommend annual eGFR and urine albumin-to-creatinine ratio monitoring for all patients with diabetes [12]. A woman with diabetes on Prometrium who adds creatine should have a urine albumin-to-creatinine ratio on file, since albuminuria detects early nephropathy before creatinine rises.
Older Postmenopausal Women
Muscle mass declines with age (sarcopenia affects an estimated 10 to 40% of women over 60) [13], which actually lowers baseline creatinine in many postmenopausal patients. Paradoxically, this makes creatine's creatinine-elevating effect more visible as a percentage change from baseline. A creatinine that rises from 55 µmol/L to 75 µmol/L after creatine loading may look alarming despite both values remaining within normal limits. Documenting the pre-supplementation baseline is especially useful in this population.
What Current Guidelines Say About Supplement-Drug Interactions in HRT
The Endocrine Society's 2015 clinical practice guideline on menopausal hormone therapy does not specifically address creatine, nor does the NAMS 2022 Hormone Therapy Position Statement [6]. Both documents recommend reviewing all over-the-counter supplements with the prescriber at the time HRT is initiated, a recommendation that directly applies here.
The NAMS 2022 position statement noted: "Patients should be counseled that many supplements and herbal products lack rigorous safety and efficacy data, and their interactions with hormone therapies are often unstudied" [6]. While creatine is better-studied than most supplements, this principle still supports open communication between patient and prescriber.
Frequently asked questions
›Can I take creatine while on Oral Micronized Progesterone?
›Does creatine interact with Oral Micronized Progesterone?
›Will creatine affect my Prometrium dose or blood levels?
›How much does creatine raise creatinine levels?
›Should I get a kidney function test before starting creatine on HRT?
›Is creatine safe for postmenopausal women?
›Can creatine affect hormone levels?
›What dose of creatine should I use if I am on Prometrium?
›Should I separate my Prometrium and creatine doses by time?
›Does creatine cause kidney damage?
›What labs should my doctor monitor if I take both creatine and Prometrium?
References
- FDA. Prometrium (progesterone, USP) Capsules 100 mg and 200 mg. Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019781s030lbl.pdf
- De Lignieres B, Dennerstein L, Backstrom T. Influence of route of administration on progesterone metabolism. Maturitas. 1995;21(3):251-257. https://pubmed.ncbi.nlm.nih.gov/7616874/
- Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev. 2000;80(3):1107-1213. https://pubmed.ncbi.nlm.nih.gov/10893433/
- Poortmans JR, Francaux M. Long-term oral creatine supplementation does not impair renal function in healthy athletes. Med Sci Sports Exerc. 1999;31(8):1108-1110. https://pubmed.ncbi.nlm.nih.gov/10449011/
- Kreider RB, Kalman DS, Antonio J, et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. J Int Soc Sports Nutr. 2017;14:18. https://pubmed.ncbi.nlm.nih.gov/28615996/
- The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of The Menopause Society. Menopause. 2022;29(7):767-794. https://pubmed.ncbi.nlm.nih.gov/35797481/
- Shlipak MG, Matsushita K, Arnlov J, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013;369(10):932-943. https://pubmed.ncbi.nlm.nih.gov/24004120/
- Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. JAMA. 2003;289(20):2651-2662. https://pubmed.ncbi.nlm.nih.gov/12771112/
- Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103-111. https://pubmed.ncbi.nlm.nih.gov/17333341/
- Smith-Ryan AE, Cabre HE, Eckerson JM, Candow DG. Creatine supplementation in women's health: a lifespan perspective. Nutrients. 2021;13(3):877. https://pubmed.ncbi.nlm.nih.gov/33800439/
- Candow DG, Chilibeck PD, Forbes SC. Creatine supplementation and aging musculoskeletal health. Endocrine. 2014;45(3):354-361. https://pubmed.ncbi.nlm.nih.gov/24146173/
- American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes 2024. Diabetes Care. 2024;47(Suppl 1):S1-S321. https://diabetesjournals.org/care/issue/47/Supplement_1
- Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. https://pubmed.ncbi.nlm.nih.gov/30312372/